<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Greenwich Lifesciences Inc — News on 6ix</title>
<link>https://6ix.com/company/greenwich-lifesciences-inc</link>
<description>Latest news and press releases for Greenwich Lifesciences Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 30 Apr 2026 10:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/greenwich-lifesciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835784b78dffbe2df0f7fdc.webp</url>
<title>Greenwich Lifesciences Inc</title>
<link>https://6ix.com/company/greenwich-lifesciences-inc</link>
</image>
<item>
<title>Greenwich LifeSciences Provides Update Regarding Form 10-K Filing</title>
<link>https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-provides-update-regarding-form-10-k-filing</link>
<guid isPermaLink="true">https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-provides-update-regarding-form-10-k-filing</guid>
<pubDate>Thu, 30 Apr 2026 10:00:00 GMT</pubDate>
<description>STAFFORD, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on its Form 10-K filing for the fiscal year ending December 31, 2025. The Form 10-K for the fiscal year ending December 31, 2025 is still being audited by the</description>
</item>
<item>
<title>Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026</title>
<link>https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-announces-acceptance-of-abstract-at-asco-2026</link>
<guid isPermaLink="true">https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-announces-acceptance-of-abstract-at-asco-2026</guid>
<pubDate>Thu, 23 Apr 2026 10:00:00 GMT</pubDate>
<description>STAFFORD, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that an abstract has been accepted for publication at the upcoming 2026 ASCO Annual Meeting along with a corresponding poster presentation. The 2026 ASCO Annual Meetin</description>
</item>
<item>
<title>Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing</title>
<link>https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-announces-receipt-of-nasdaq-notice-regarding-late-form-10-k-filing</link>
<guid isPermaLink="true">https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-announces-receipt-of-nasdaq-notice-regarding-late-form-10-k-filing</guid>
<pubDate>Wed, 22 Apr 2026 21:00:00 GMT</pubDate>
<description>STAFFORD, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that on April 16, 2026, the Company received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, because</description>
</item>
<item>
<title>Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026</title>
<link>https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-presents-flamingo-01-phase-iii-trial-open-label-data-published-at-aacr-meeting-2026</link>
<guid isPermaLink="true">https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-presents-flamingo-01-phase-iii-trial-open-label-data-published-at-aacr-meeting-2026</guid>
<pubDate>Mon, 20 Apr 2026 10:00:00 GMT</pubDate>
<description>STAFFORD, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today presents the published abstract and poster from the AACR Meeting 2026. The abstract is shown below and the poster being presented today can be seen and downloaded at the bottom</description>
</item>
<item>
<title>Greenwich LifeSciences Provides Update on Financing Strategy</title>
<link>https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-provides-update-on-financing-strategy</link>
<guid isPermaLink="true">https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-provides-update-on-financing-strategy</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>STAFFORD, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company</description>
</item>
<item>
<title>Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential</title>
<link>https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-provides-update-on-patent-claims-potentially-doubling-gp2-market-potential</link>
<guid isPermaLink="true">https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-provides-update-on-patent-claims-potentially-doubling-gp2-market-potential</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>STAFFORD, Texas, April 07, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company</description>
</item>
<item>
<title>Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01</title>
<link>https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-announces-addition-of-city-of-hope-to-flamingo-01</link>
<guid isPermaLink="true">https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-announces-addition-of-city-of-hope-to-flamingo-01</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>STAFFORD, Texas, March 19, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company</description>
</item>
<item>
<title>Greenwich LifeSciences Provides Update on Upcoming AACR Meeting</title>
<link>https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-provides-update-on-upcoming-aacr-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-provides-update-on-upcoming-aacr-meeting</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>STAFFORD, Texas, March 18, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company</description>
</item>
<item>
<title>Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01</title>
<link>https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-provides-update-showing-continued-reduction-in-recurrence-rate-in-the-open-label-arm-of-flamingo-01</link>
<guid isPermaLink="true">https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-provides-update-showing-continued-reduction-in-recurrence-rate-in-the-open-label-arm-of-flamingo-01</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>STAFFORD, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company</description>
</item>
<item>
<title>Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01</title>
<link>https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-announces-use-of-commercially-manufactured-gp2-in-flamingo-01</link>
<guid isPermaLink="true">https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-announces-use-of-commercially-manufactured-gp2-in-flamingo-01</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>STAFFORD, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company</description>
</item>
<item>
<title>Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01</title>
<link>https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-provides-update-on-increased-patient-screen-rate-in-flamingo-01</link>
<guid isPermaLink="true">https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-provides-update-on-increased-patient-screen-rate-in-flamingo-01</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>STAFFORD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company</description>
</item>
<item>
<title>Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026</title>
<link>https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-announces-acceptance-of-two-abstracts-at-aacr-annual-meeting-2026</link>
<guid isPermaLink="true">https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-announces-acceptance-of-two-abstracts-at-aacr-annual-meeting-2026</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>STAFFORD, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company</description>
</item>
<item>
<title>Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy</title>
<link>https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-provides-flamingo-01-110000826</link>
<guid isPermaLink="true">https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-provides-flamingo-01-110000826</guid>
<pubDate>Tue, 27 Jan 2026 11:00:00 GMT</pubDate>
<description>STAFFORD, Texas, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided additional updates on its cash burn rate and financing strategy. The Company's ATM financing vehicle allows the Company to sell its common stock directly into the tradin</description>
</item>
<item>
<title>Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01</title>
<link>https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-announces-fda-approves-110000185</link>
<guid isPermaLink="true">https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-announces-fda-approves-110000185</guid>
<pubDate>Thu, 22 Jan 2026 11:00:00 GMT</pubDate>
<description>STAFFORD, Texas, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the use of commercially manufactured GP2 in FLAMINGO-01. FDA Reviews and Approves Use of 1st GP2 Commercial Lot in FLAMINGO-01 The first three commercial lots of GP2 a</description>
</item>
<item>
<title>Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026</title>
<link>https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-extends-lock-directors-110000362</link>
<guid isPermaLink="true">https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-extends-lock-directors-110000362</guid>
<pubDate>Mon, 29 Dec 2025 11:00:00 GMT</pubDate>
<description>STAFFORD, Texas, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to September 30, 2026 whic</description>
</item>
<item>
<title>Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy</title>
<link>https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-provides-additional-updates-110000950</link>
<guid isPermaLink="true">https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-provides-additional-updates-110000950</guid>
<pubDate>Mon, 22 Dec 2025 11:00:00 GMT</pubDate>
<description>STAFFORD, Texas, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided additional updates on FLAMINGO-01 and the Company’s corporate strategy. Corporate Strategy The Company recently attended a Noble Capital conference on December 3, 2025,</description>
</item>
<item>
<title>Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01</title>
<link>https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-announces-preliminary-analysis-110000559</link>
<guid isPermaLink="true">https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-announces-preliminary-analysis-110000559</guid>
<pubDate>Mon, 15 Dec 2025 11:00:00 GMT</pubDate>
<description>STAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced an approximately 80% recurrence rate reduction in the open label non-HLA-A*02 arm of FLAMINGO-01. A preliminary analysis of recurrence rates by two methods to estimate the reduction in recur</description>
</item>
<item>
<title>Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01</title>
<link>https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-announces-completion-enrollment-110000937</link>
<guid isPermaLink="true">https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-announces-completion-enrollment-110000937</guid>
<pubDate>Mon, 08 Dec 2025 11:00:00 GMT</pubDate>
<description>STAFFORD, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the completion of enrollment in the open label non-HLA-A*02 arm of FLAMINGO-01. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients are currently planned t</description>
</item>
<item>
<title>Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01 </title>
<link>https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-announces-completion-of-enrollment-in-the-open-label-arm-of-flamingo-01</link>
<guid isPermaLink="true">https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-announces-completion-of-enrollment-in-the-open-label-arm-of-flamingo-01</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>STAFFORD, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company</description>
</item>
<item>
<title>Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date</title>
<link>https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-provides-global-flamingo-110000423</link>
<guid isPermaLink="true">https://6ix.com/company/greenwich-lifesciences-inc/news/greenwich-lifesciences-provides-global-flamingo-110000423</guid>
<pubDate>Wed, 03 Dec 2025 11:00:00 GMT</pubDate>
<description>STAFFORD, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following global update on FLAMINGO-01. Flamingo-01 Progress to Date The Company has achieved a major milestone by screening over 1,000 patients in Flamingo-01, continuing its screening r</description>
</item>
</channel>
</rss>